ReviewWorld journal of clinical cases2019
Diagnostic-therapeutic management of bile duct cancer.
Review in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pooled it
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFuture oncology (London, England) · 2020Trial
- Initial Biliary Drainage in Unresectable Bismuth Type III Malignant Hilar Obstruction: Comparative Effectiveness of ERCP and PTBD According to Drainage Adequacy in a Retrospective Two-Center Study.Journal of clinical medicine · 2026Article
- Prognostic Role of Circulating DNA in Biliary Tract Cancers: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US.The oncologist · 2025Article
- Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer.International journal of clinical oncology · 2024Observational
- New perspectives in biliary tract cancers.ESMO gastrointestinal oncology · 2024Review
- Article
- Editorial: Biomarkers and immunotherapy of hepatic-biliary-pancreatic cancers.Frontiers in oncology · 2023Article
- Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.The oncologist · 2022Article
- Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.Targeted oncology · 2022Article
- Surgical outcomes and prognostic factors of distal common bile duct adenocarcinoma: chronological analysis in a single high-volume institutional experience.BMC surgery · 2022Article
- Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.Scientific reports · 2021Article
- Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review.Cancer management and research · 2021Review
- Article
- [European journal of nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biliary tract cancer, or cholangiocarcinoma, comprises a heterogeneous group of malignant tumors that can emerge at any part of the biliary tree. This group is the second most common type of primary liver cancer. Diagnosis is usually based on symptoms, which may be heterogeneous, and nonspecific biomarkers in serum and biopsy specimens, as well as on imaging techniques. Endoscopy-based diagnosis is essential, since it enables biopsy specimens to be taken. In addition, it can help with locoregional staging of distal tumors. Endoscopic retrograde cholangiopancreatography is a key technique for the evaluation and treatment of malignant biliary tumors. Correct staging of cholangiocarcinoma is essential in order to be able to determine the degree of resectability and assess the results of treatment. The tumor is staged based on the TNM classification of the American Joint Committee on Cancer. The approach will depend on the classification of the tumor. Thus, some patients with early-stage disease could benefit from surgery; complete surgical resection is the cornerstone of cure. However, only a minority of patients are diagnosed in the early stages and are suitable candidates for resection. In the subset of patients diagnosed with locally advanced or metastatic disease, chemotherapy has been used to improve outcome and to delay tumor progression. The approach to biliary tract tumors should be multidisciplinary, involving experienced endoscopists, oncologists, radiologists, and surgeons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.